SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and adoption by major players. Chatter revolves around Pyth's role in the Real World Asset (RWA) space, with some speculating on future price targets. Discussions also highlight the potential impact of institutional adoption and expansion into new markets.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining attention as community members suggest it's primed for a breakout, with many highlighting its potential for significant gains. The conversation centers around accumulating positions, with some comparing it to early opportunities in other successful crypto projects. Others suggest $AINAL.X represents a strategic move by 'smart money' within the crypto space.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst heated discussions surrounding a recent tragedy, with community members expressing strong opinions and political divides seemingly amplified.  Conversations are centered on the motivations and affiliations of individuals involved, sparking debates about extremist ideologies and the impact of political rhetoric.  The stock's movement is secondary to the intense social and political commentary.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price rallies, fueled by momentum in its energy business and speculation around future AI and robotics initiatives. The community is actively debating whether this surge is justified by fundamentals or driven by market manipulation, with some pointing to a potential short squeeze while others highlight concerns about insider selling and product safety. Discussions also include broader market conditions and potential impacts on the EV sector.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss the potential impact of treasury companies and a large purchase from Galaxy Digital, speculating on a possible surge toward new price levels. The conversation includes discussion around meme coins on the Solana network. Some users are suggesting that Solana could overtake other cryptocurrencies in market capitalization.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight its strong chart setup, coiling pattern, and potential for a breakout. Discussions revolve around accumulation phases, steady bullish momentum, and the anticipation of a significant upward move. The community also notes growing awareness and potential partnerships, contributing to the bullish sentiment.

Trump For President

The TRUMP.X crypto is trending amid discussions about a potential ETF and its correlation with other cryptos like BTC and ETH. Community members are debating its future value, especially if Trump actively supports or acknowledges the coin, while also commenting on his recent summit with Putin. Political opinions and sentiments toward Trump are heavily influencing the conversation around this speculative asset.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community celebrates upcoming exchange listings and anticipates airdrops at the 5M market cap milestone. Talk centers around the project's organic growth, strong community engagement, and ongoing development efforts like staking and a mobile app. Community members express excitement about the potential for significant gains within the Solana ecosystem.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as the community discusses potential breakouts and compares it to other meme coins like Doge and Shib. Some users are expressing frustration with price fluctuations, while others remain optimistic about long-term gains and potential rallies. The conversation also includes mentions of potential market manipulation and the broader meme coin sector.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 EFZO-FIT data, expected mid-September, focusing on pulmonary sarcoidosis treatment. The community is actively discussing aggressive ask-side put sweeps, high implied volatility, and potential binary gap risk, while also debating the significance of recent analyst ratings and commercial hires. Some traders are weighing defined-risk setups and hedging strategies amid the uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for August 22nd

INKT, MNR and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2025.

MiNK Therapeutics stock falls after William Blair downgrade

Investing.com -- MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer following treatment with its cell therapy.<a href="https://stocktwits.com/symbol/INKT">INKT shares</a> were up about 466% at the time of writing.The patient had progressed after multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and multiple immune checkpoint inhibitors.However, they had complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later, after receiving a single infusion of agenT-797 alongside the cancer drug nivolumab.AgenT-797 is an off-the-shelf, cryopreserved invariant natural killer T (iNKT) cell therapy. It utilizes iNKT cells, which contribute to anti-tumor effects, from a healthy donor to treat a recipient.Donor iNKT cells were detectable up to six months post-infusion in the patient, and treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-publication-complete-remission">said</a>.AgenT-797 is currently in clinical development for graft-versus-host disease (GvHD), solid tumors, and severe pulmonary inflammation. The company said that its ongoing mid-stage trial in gastric cancer is actively enrolling, with data readouts expected in the coming months.On Stocktwits, retail sentiment around INKT jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_9_59_40_AM_png_9597d54c42.webp" alt="INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>INKT's Sentiment Meter and Message Volume as of 10 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company would have a share offering in the evening as it “absolutely” needs more money.<stembedurl>https://stocktwits.com/pow7904/message/620632189</stembedurl>MiNK ended the first quarter with a cash balance of $3.2 million.INKT stock is up by about 519% this year and by about 345% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/levi-stock-surges-after-analysts-raise-price-target-on-stock-retail-sentiment-extremely-bullish/ch8cXLQR5ZF">Levi Stock Surges After Analysts Raise Price Target On Stock, Retail Sentiment ‘Extremely Bullish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy

“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.

Equity

Why MiNK Therapeutics Stock Is Up 11% Monday

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
read more...

HC Wainwright Lowers MiNK Therapeutics (NASDAQ:INKT) Price Target to $9.00

MiNK Therapeutics (NASDAQ:INKT  Free Report) had its target price reduced by HC Wainwright from $10.00 to $9.00 in a report released on Thursday morning, Benzinga reports. They currently have...

Q4 2023 Mink Therapeutics Inc Earnings Call Transcript

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development...

Earnings Outlook For MiNK Therapeutics

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...

MiNK Therapeutics announces preclinical data from MiNK-215

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.86	--	--	N/A
Q2 '25	-$0.55	-$1.06	-93.90%	MISSED
Q1 '25	-$0.61	-$0.70	-15.19%	MISSED
Q4 '24	-$0.48	-$0.62	-29.17%	MISSED
Q3 '24	-$0.08	-$0.50	-524.48%	MISSED

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest INKT News

INKT MiNK Therapeutics Inc